A multivariable analysis suggested the safety and efficacy of onasemnogene abeparvovec (OA) in the treatment of older and heavier children with spinal muscular atrophy (SMA) type 1.
No serious long-term safety issues were recorded with the use of the gene therapy onasemnogene abeparvovec (OA; Zolgensma) in the treatment of children with spinal muscular atrophy (SMA) type 1, according to a study published in The Lancet Regional Health – Europe.
Baby feet | Image credit: Simon Dannhauer - stock.adobe.com
OA is 1 of 3 approved therapies in the treatment of SMA and utilizes a vector of a genetically modified adeno-associated virus type 9 (AAV9) in its stimulation of functional SMN protein production. As authors of the present study note, multiple previous studies have demonstrated that OA can provide benefits to the survival and motor function of children under 2 years of age with SMA types 1 and 2; however, data on the efficacy and safety of OA in children beyond 2 years, as well as those weighing more than 13.5 kg, is lacking.
To address this gap in knowledge, researchers conducted a multi-center analysis in the UK to gather real-world data on the use of OA in patients with SMA type 1, which included those 2 years of age or older and weighing at least 13.5 kg.
Data were gathered on pediatric patients with SMA type 1 administered OA from May 2021 to January 2023. Researchers analyzed patients in conjunction with the SMAREACH registry throughout 6 UK infusion centers. Individuals’ platelet counts, liver function, need for steroids, and cardiac assessments were evaluated in the safety analysis of OA. Additional scales such as the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND), Hammersmith Infant Neurological Examination (HINE), and Revised Hammersmith Scale (RHS) were used in patient assessments. Investigators reviewed the highest individual score achieved during follow-ups as well as scores 2 weeks prior. Furthermore, patients were categorized according to their age and weight at the time of infusion: younger than 6 months, 6 to 12 months, 1 to 2 years, older than 2 years; and less than 8.5 kg, 8.5 to 13.5 kg, and at least 13.5 kg.
A total of 99 patients with SMA treated with OA were included, 45 of whom were treatment naïve. The other 54 patients were referred to as the pre-treatment cohort. Twenty-one patients were at least 2 years old and 7 were at least 13.5 kg. Follow-ups ranged between 3 and 22 months.
CHOP-INTEND scores were available before and after OA initiation for 78 patients. Overall, 84.6% (66) of patients registered increases in their scores, with a mean change of 11 points across the cohort. Notably, patients younger than 6 months had statistically significant increases in CHOP-INTEND over patients aged 2 years or older (13.9-point gains; 95% CI, 6.8-21.0; P < .001). Each age group trended positively in this regard; however, patients aged younger than 6 months experienced significantly higher estimated increases than both patients aged 6 to 12 months (P = .03) and those 12 to 24 months of age (P < .001).
Those who completed RHS and HINE assessments also demonstrated functional scoring increases, but these examinations were not done across the majority of the cohort.
Investigators witness that a patient’s weight at infusion was positively correlated with steroid administration (P < .001). For each increase of 5 kg of weight, individuals were linked to 46% longer durations of steroid use (95% CI, 24.1%-71.7%). Furthermore, the multivariable analysis revealed that there was also an association between age of infusion with OA and steroid duration (P < .001), with each 1-year age increase associating with a 13.8% extended period of steroid therapy (95% CI, 7.2%-20.7%).
The authors note that hepatoxicity was also more associated with increased weights in these patients, and that a few endured worsening transaminitis; however, any clinical issues were nonpersistent in older and heavier patients. As OA treatment was well-tolerated and contributed to functional betterment, these findings demonstrate the safety and efficacy of OA in this population.
Reference
Gowda V, Atherton M, Murugan A, et al. Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom. Lancet Reg Health Eur. Published online December 11, 2023. doi:10. 1016/j.lanepe.2023.100817
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More